SGL Investment Advisors Inc. Acquires Shares of 1,698 Danaher Corporation $DHR

Key Points

• SGL Investment Advisors Inc. has acquired 1,698 shares of Danaher Corporation valued at approximately $341,000, as reported in their recent SEC filing.
• Danaher reported earnings of $1.80 per share, exceeding expectations, while revenue increased by 3.4% year-over-year, reaching $5.94 billion.
• The company declared a quarterly dividend of $0.32 per share, with a payout set for October 31st, representing an annual yield of 0.6%.

SGL Investment Advisors Inc. bought a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,698 shares of the conglomerate's stock, valued at approximately $341,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. lifted its position in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after buying an additional 99 shares during the period. Sierra Ocean LLC boosted its stake in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after acquiring an additional 76 shares in the last quarter. Red Tortoise LLC grew its stake in shares of Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate's stock worth $30,000 after acquiring an additional 98 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in shares of Danaher in the 1st quarter worth $31,000. Finally, Dunhill Financial LLC boosted its position in shares of Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after buying an additional 67 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on DHR. Wells Fargo & Company cut their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a report on Friday, July 11th. Barclays reiterated an "overweight" rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Evercore ISI reduced their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Seventeen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $245.91.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 11.10% of the company's stock.

Danaher Stock Down 1.6%

Shares of DHR stock opened at $211.65 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The company's fifty day moving average price is $200.36 and its 200-day moving average price is $197.24. The company has a market capitalization of $151.55 billion, a price-to-earnings ratio of 45.03, a PEG ratio of 3.06 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.